Following the determination of the FTO crystal structure by Chai's group in 2010 (Figure 5B) (143), FTO is widely viewed as an attractive biological target; potentially a small-molecule inhibitor specifically targeting FTO could be developed for the treatment of metabolic disorders such as obesity and diabetes. This evidence concerns the gene FTO and Obesity.